Tamibarotene
- Generic Name
- Tamibarotene
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25NO3
- CAS Number
- 94497-51-5
- Unique Ingredient Identifier
- 08V52GZ3H9
- Background
Tamibarotene is a novel synthetic retinoid for acute promyelocytic leukaemia (APL). Tamibarotene is currently approved in Japan for treatment of recurrent APL, and is undergoing clinical trials in the United States.
- Indication
Investigated for use/treatment in leukemia (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
Rege Nephro Co., Ltd. Successfully Completes Series B Funding to Accelerate Kidney ...
Rege Nephro Co., Ltd. raised 22.5 billion yen in Series B funding, totaling 44 billion yen. The funds will advance RN-014's Phase II trials for ADPKD and prepare for U.S. trials, plus support RN-032's preclinical trials for CKD.
Exploring Advancements in Higher-Risk MDS
Despite challenges in improving treatment for high-risk myelodysplastic syndrome (HR-MDS), advancements in combination therapies and molecular profiling offer hope. Allogeneic transplantation remains the only curative option, but posttransplant relapse is a concern. Recent trials combining azacitidine with various drugs showed promise but failed to outperform monotherapy in phase 3. Future potential lies in targeted treatments like azacitidine with venetoclax or tamibarotene, and refining response criteria. Molecular findings are crucial for more precise treatment design.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath